frontiers | Frontiers in Neurology

TYPE Correction
PUBLISHED 01 August 2024
DOI 10.3389/fneur.2024.1460992

OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Guangyao Li
425293675@qq.com
Min Li
doctorlimin@gzucm.edu.cn
Jia Xiong
12366104@qq.com

RECEIVED 07 July 2024
ACCEPTED 15 July 2024
PUBLISHED 01 August 2024

CITATION
Huang Y, Tan T, Liu L, Yan Z, Deng Y, Li G, Li M and Xiong J (2024) Corrigendum: Exercise for reducing chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis of randomized controlled trials. *Front. Neurol.* 15:1460992. doi: 10.3389/fneur.2024.1460992

Corrigendum: Exercise for reducing chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis of randomized controlled trials

Yingjie Huang[1], Tian Tan[2], Lu Liu[3], Zijian Yan[3], Yuexia Deng[4], Guangyao Li[5]*, Min Li[2]* and Jia Xiong[6]*

[1]Guangzhou University of Chinese Medicine, Guangzhou, China, [2]Clinical Medical College of Acupuncture Moxibustion and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, China, [3]The First Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China, [4]Southern Theater General Hospital, Guangzhou, China, [5]Department of Traditional Chinese Medicine, Guangdong Provincial Key Laboratory ofMajor Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, [6]Nanchang Hongdu Hospital of Traditional Chinese Medicine, Nanchang, Jiangxi Province, China

KEYWORDS

exercise therapy, chemotherapy-induced peripheral neuropathy, CIPN, efficacy, meta-analysis

A corrigendum on
Exercise for reducing chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis of randomized controlled trials

by Huang, Y., Tan, T., Liu, L., Yan, Z., Deng, Y., Li, G., Li, M., and Xiong, J. (2024). *Front. Neurol.* 14:1252259. doi: 10.3389/fneur.2023.1252259

In the published article, there was an error in [Figures 3–10 and Table 1] as published. [The figures and table incorrectly list studies with first names of the authors, instead of last names]. The corrected [Figures 3–10 and Table 1] and their captions appear below.

In the published article, there was an error in [Supplementary Figures 1–3]. [The supplementary figures incorrectly list studies with first names of the authors, instead of last names]. The correct material statement published in online.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

TABLE 1 The basic characteristics of the included studies.

Trail	Country	Sample size (T/C)	Age (y), Mean ± SD or median (Range)		Duration/W		T	C	Main outcomes	Frequency	Follow-up time/week	Cancer	Chemotherapy
			T	C	T	C							
Simşek et al. (29)	Turkey	30, 30/30	>18y	>8y	NA	NA	Stretching exercise + balance exercise	Chemotherapy + usual care	①②	5 times/ Week	12	Breast cancer	Taxane
Kleckner et al. (25)	USA	170/185	55.6 ± 11.8	55.9 ± 9.7	12.1 ± 60.9	5.7 ± 10.0	Strength training	Chemotherapy	①③	60 min, qd	6	Breast/ Lymphoma/ Colon/ Lung cancer	Taxane-, platinum-, or vinca alkaloid
Ikio et al. (24)	Japan	19/20	69 (60–89)	64 (57–87)	5 (2–111)	6 (2–93)	Strength training	Chemotherapy	①②	30 min, tiw	NA	Hematological malignancy/ Gastrointestinal cancer	Vinca alkaloids, taxanes, platinum compounds and proteasome inhibitors
Gui et al. (23)	China	51/28	50 ± 8	52 ± 7	12 (23.5)	6 (21.4)	Sensory exercise	Chemotherapy	②③⑤	qd	2	Digestive malignancies	Oxaliplatin
Bao et al. (21)	USA	21/20	60.0 (35.5, 77.9)	62.3 (42.4, 79.0)	3.1 (0.5, 10.4)	3.7 (0.9, 15.3)	Yoga	Chemotherapy + usual care	①③⑤	60 min, qd	8	Breast/ Uterine/ Ovarian cancer	Taxane-, platinum-, or vinca alkaloid
Dhawan et al. (22)	India	22/23	50.5 ± 7.9	52.5 ± 6.6	10.2 ± 7.8	9.8 ± 8.6	Strength training	Chemotherapy	①②③	30 min, qd	10	Ovarian/ Cervical/ Lung cancer	Paclitaxel, carboplatin

(Continued)

10.3389/fneur.2024.1460992

TABLE 1 (Continued)

Trail	Country	Sample size (T/C)	Age (y), Mean ± SD or median (Range)		Duration/W		T	C	Main outcomes	Frequency	Follow-up time/week	Cancer	Chemotherapy
			T	C	T	C							
Müller et al. (27)	Germany	49, 57/57	51.7 ± 10.8/53.4 ± 11.7	54.5 ± 11.9	22.0 ± 9.3/23.5 ± 8.9	23.0 ± 9.4	Sensory exercise/ strength training	Chemotherapy	①	35min, tiw	NA	NA	Taxanes, platinum derivatives, vinca alkaloids
Schwenk et al. (28)	USA	11./11	68.73 ± 8.72	71.82 ± 8.85	49.91 ± 44.11	44.63 ± 56.78	Balance exercise	Chemotherapy + health education	④	45 min, biw	4	NA	NA
Vollmers et al. (31)	Germany	17/19	48.56 ± 11.94	52.39 ± 10.14	12	12	Sensory exercise	Chemotherapy + health education	④	60 min, biw	12	Breast cancer	Taxane
Zimmer et al. (33)	Germany	17/13	68.53 (50–81)	70.00 (50–81)	27.94 ± 24.557	24.38 ± 19.692	Strength training + balance exercise	Chemotherapy + health education	②④⑤	60 min, biw	8	Colon cancer	Bevacizumab, regorafenib, trastuzumab
Huang et al. (26)	China	32/34	54.56 ± 9.4	57.65 ± 9.8	4.66 ± 1.10	4.79 ± 1.06	Aerobic exercise	Chemotherapy + usual care	①②③	30 min, biw	6	Ovarian cancer	Taxane-, platinum-, or vinca alkaloid
Peng et al. (32)	China	23/23	53.17 ± 9.29	52.15 ± 7.25	NA	NA	Balance exercise	Chemotherapy + usual care	①②③⑤	15–30 min, tiw	12	Breast/ Lymphoma cancer/ Myeloma	Taxanes, platinum, vincristine, bortezomib, thalidomide
Visovsky et al. (30)	USA	19/19	48.8 (24–65)	48.8 (24–65)	NA	NA	Aerobic exercise + strength training	Chemotherapy + health education	①②④	30 min/ time, 5–7 times/ Week	12	Breast cancer	Taxane
Streckmann et al. (50)	Germany	28/28	44 (20–67)	48 (19–73)	NA	NA	Aerobic exercise + strength training	Chemotherapy	②③	biw	36	Lymphoma cancer	Taxanes, platinum, vincristine, bortezomib, thalidomide
Andersen et al. (20)	Canada	22/26	56.3 ± 9.9	53 ± 10.3	NA	NA	Stretching exercise	Chemotherapy + usual care	①	4 times/ Week	6	Breast cancer	Taxane

T, trial group; C, control group; NA, not reported; ① symptom score (total symptom score, numbness, and tingling); ② quality of life score (total score, physical, functional, social, emotional, and neurotoxicity); ③ pain; ④ balance; ⑤ functional assessment of neurotoxicity (FACT/GOG-NTX); qd, once a day; biw, 2 times/week; tiw, 3 times/week.

10.3389/fneur.2024.1460992



FIGURE 3
Forest plot. **(A)** Total symptom score. **(B)** Total symptom score after excluding two trail.



FIGURE 4
Forest plot of numbness.



FIGURE 5
Forest plot of tingling.

10.3389/fneur.2024.1460992



FIGURE 6
Forest plot of quality of life score.

10.3389/fneur.2024.1460992



FIGURE 7
Forest plot of physical, functional, social, emotional, and neurotoxicity.



FIGURE 8
Forest plot. **(A)** Pain. **(B)** Balance.



FIGURE 9
Forest plot of FACT/GOG-NTX.

10.3389/fneur.2024.1460992



FIGURE 10
Funnel plot of the total symptom score.